Experts make new recommendations on RSV and meningitis vaccines, but it's unclear what happens next
ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis.
The Advisory Committee on Immunization Practices also voted to recommend a shot to protect travelers from a mosquito-borne illness called chikungunya.
But it's not clear who will decide whether to accept those recommendations.
The 15-member expert panel makes recommendations to the director of the Centers for Disease Control and Prevention on how regulator-cleared vaccines should be used. CDC directors almost always approve the recommendations.
The Trump administration named Susan Monarez as acting CDC director in January, and last month picked her to lead the agency. But while she's awaiting Senate confirmation, she has essentially recused herself from regular duties because of federal law around vacancies, according to two CDC officials speaking on condition of anonymity because they were not authorized to discuss agency matters and feared being fired.
That means any committee recommendations made Wednesday may move to U.S. Health Secretary Robert F. Kennedy Jr., a leading voice in the U.S. anti-vaccine movement.
A Department of Health and Human Services spokesperson has told The Associated Press he was looking into how the agency would decide on the panel's recommendations.
Those recommendations on Wednesday were:
— People 50 to 59 should be able to get vaccinated against respiratory syncytial virus have risks including heart disease, diabetes and chronic obstructive pulmonary disorder.
— Endorsement of a new combination shot made by GSK that protects against five strains of meningococcal bacteria, including a strain that caused a spate of outbreaks on college campuses about 10 years ago. It would join other products that also target the germs.
— Adding a second chikungunya vaccine to the options for Americans age 12 and older who are traveling to countries where outbreaks are occurring. About 100 to 200 cases are reported annually among U.S. travelers.
— Adding a new precaution for the older chikungunya vaccine that uses weakened but live virus: People 65 and older should weigh the risks of benefits of that version of the shot, the panel said. The precaution was added after panel members heard about an investigation into six reports of people 65 and older — most of them with other medical problems — who became ill with heart or brain symptoms less than a week after vaccination. The investigation is continuing.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest's Substack. In this article, we will summarize the bulls' thesis on REGN. Regeneron Pharmaceuticals, Inc. (REGN)'s share was trading at $605.39 as of 29th May. REGN's trailing and forward P/E were 15.39 and 17.39 respectively according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Regeneron's latest earnings report was notably weak, with a 3.7% revenue decline and a 14% EPS drop, surprising given the company's history of exceeding market expectations. The primary driver was a steep 26% year-over-year decline in the U.S. Eylea franchise, particularly a 39% drop in 2mg Eylea sales. This was partly due to a co-pay assistance funding gap, which forced many Medicare patients to switch to cheaper alternatives like compounded Avastin, impacting both Regeneron and rival Roche's Vabysmo. Regeneron, having contributed over $400 million last year to charitable foundations supporting co-pay assistance, is now seeking to share this burden, proposing a matching donation program to encourage broader industry support. Another setback was the FDA's Complete Response Letter delaying approval of the Eylea-HD pre-filled syringe, a key product needed to compete with Vabysmo. The delay stemmed from third-party component issues rather than drug efficacy, and management believes resolution could be near. Margins also contracted, with gross margin falling from 89% to 85% due to unspecified inventory write-offs, possibly related to older Eylea 2mg or even leftover REGEN-COV stock. However, the margin pressure appears more tied to one-offs and increased R&D spending than structural issues. On a more positive note, Regeneron's pipeline is broadening meaningfully. Itepekimab, an IL-33 antibody, shows promise as a major respiratory asset with pivotal COPD data upcoming and expanded trials underway. The growing RNAi pipeline, now at nine siRNAs through its Alnylam collaboration, signals Regeneron's potential evolution beyond antibodies into a broader genetic medicine powerhouse. Regeneron Pharmaceuticals, Inc. (REGN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held REGN at the end of the first quarter which was 68 in the previous quarter. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
37 minutes ago
US measles cases nearing 30-year high
The number of measles cases in the U.S. this year has quadrupled compared to 2024 and is nearing a 30-year high. As of Friday, there have been 1,168 confirmed measles cases across 33 states nationwide, according to data from the Centers for Disease Control and Prevention. Last year, the U.S. saw just 285 measles cases, CDC data shows. The U.S. is currently on track for the highest number of measles case since 2019. The 33 states with confirmed cases include Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Virginia and Washington. Among the nationally confirmed cases, the CDC says 95% are among people who are unvaccinated or whose vaccination status is unknown. Meanwhile, 2% of cases are among those who have received just one dose of the measles, mumps, rubella (MMR) vaccine and 3% of cases are among those who received the required two doses, according to the CDC. At least two school-aged children have died. Both were unvaccinated and had no known underlying conditions, according to Texas health officials said. A third measles death was recorded in New Mexico among an unvaccinated adult who tested positive after dying, according to the New Mexico Department of Health.
New York Times
an hour ago
- New York Times
Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns
The Centers for Disease Control and Prevention's plans to consolidate data on diseases like measles and polio are raising concerns about patient privacy, delays in spotting long-term trends and ways the Trump administration may use the information. The agency told state officials earlier this week that it would shift disease information to a new system managed by Palantir, the data analysis and technology firm co-founded by Peter Thiel. The change is not entirely unexpected. The Covid pandemic revealed that the C.D.C.'s data systems were antiquated, hobbling the country's response in the crucial early months. A plan to modernize and consolidate the agency's data systems began during the Biden administration. But news that the Trump administration has expanded Palantir's work across the federal government in recent months, allowing it to compile detailed information about Americans, has introduced a new layer of anxiety and mistrust among state and local officials about sharing data with the C.D.C. Palantir's systems, including those at the C.D.C., rely on a platform called Foundry that could merge information from different agencies. The Department of Health and Human Services, the Food and Drug Administration and the National Institutes of Health all use Foundry. Some officials worry that a sprawling data collection system could expose or endanger people with sensitive health needs, like gender care, reproductive health care or disabilities. Some labor and other advocacy groups have tried to block the Trump administration from sharing data across agencies. Want all of The Times? Subscribe.
